Abstract

PHARMACOECONOMICS EVALUATION OF TELMISARTAN AS MONOTHERAPY COMPARED WITH TELMISARTAN PLUS HYDROCHLOROTHIAZIDE AS COMBINATION THERAPY IN HYPERTENSIVE PATIENTS

Md Nematullah*, Rizwana Parveen, Rajveer Singh, Ranjeet Kumar

ABSTRACT

Background: Hypertension is silent killer it is not a disease it is a disorder. The Pharmacoeconomics study focuses on cost and benefit of the therapy. Monotherapy compared with the combination therapy. Aim: The aim of study to evaluate cost-effectiveness of telmisartan as monotherapy compared with telmisartan plus hydrochlorothiazide as combination therapy in hypertensive patients in tertiary care teaching hospital, Jaipur. Methods: A prospective observational study of six month conducted on the hypertension patients at general male medicine ward and female medicine ward with n=80 patients. A systemic protocol followed to obtained permission Institutional Ethical Committee (IEC) by submitting a proper protocol, data collection form, patient information and patient consent form. Result: Out of 80 patients it was found that in the study the cost of telmisartan was less and more cost-effectiveness as compare to telmisartan plus HCTZ. Conclusion: Telmisartan is a cost-saving therapy compared with Telmisartan plus HCTZ in HTN patients.

Keywords: Telmisartan, Telmisartan plus hydrochlorothiazide, Hypertension.